(Total Views: 587)
Posted On: 04/14/2020 6:03:43 PM
Post# of 148892
This alleged 1M dose order (which I don't doubt -- but which requires confirmation) is interesting from the standpoint that NP asserted several times before COVID became real -- that CytoDyn had 40k doses in-hand, would be receiving 100k doses in Q2-2020, and an additional 500k doses in 2H-2020.
Now, we know there are ongoing trials, there are compassionate use requirements, there are trials possibly beginning soon for protocols already filed with the FDA, there are maybe new trials that might be possible if we have near term revenue, and product required for the commercial roll-out of the Combo HIV indication by Vyera (a couple of months after anticipated FDA approval).
The question in my mind is -- how does this alleged 1M dose order square with the product that was already discussed as being in the pipeline (100k + 500k = 600k).
And, is this 1M dose order above and beyond the existing 600k we thought was already coming in -- or is it only 400k more that what we already needed (600k + 400k = 1M)?
Also, I remember hearing that Samsung had agreed to defer payment for the doses already conceived before COVID until Q1-2021 (although I could be mistaken). So, whether the 1M being discussed is inclusive of what was already ordered, or additive on top of what was already ordered, how are we paying for this?
I guess NP might have represented to Samsung that he'd be able to sell the COVID doses to global customers if the FDA did not approve -- thereby providing Samsung with hard dollars 6-months before they would have otherwise received them.
I also wonder if NP is allowing Samsung to increase production beyond the 1M doses, and giving them a license to sell into the SK market -- which solves a local COVID problem and also probably generates profit.
Bottom Line: It would be interesting to understand the machinations of this deal, assuming there is one.
Now, we know there are ongoing trials, there are compassionate use requirements, there are trials possibly beginning soon for protocols already filed with the FDA, there are maybe new trials that might be possible if we have near term revenue, and product required for the commercial roll-out of the Combo HIV indication by Vyera (a couple of months after anticipated FDA approval).
The question in my mind is -- how does this alleged 1M dose order square with the product that was already discussed as being in the pipeline (100k + 500k = 600k).
And, is this 1M dose order above and beyond the existing 600k we thought was already coming in -- or is it only 400k more that what we already needed (600k + 400k = 1M)?
Also, I remember hearing that Samsung had agreed to defer payment for the doses already conceived before COVID until Q1-2021 (although I could be mistaken). So, whether the 1M being discussed is inclusive of what was already ordered, or additive on top of what was already ordered, how are we paying for this?
I guess NP might have represented to Samsung that he'd be able to sell the COVID doses to global customers if the FDA did not approve -- thereby providing Samsung with hard dollars 6-months before they would have otherwise received them.
I also wonder if NP is allowing Samsung to increase production beyond the 1M doses, and giving them a license to sell into the SK market -- which solves a local COVID problem and also probably generates profit.
Bottom Line: It would be interesting to understand the machinations of this deal, assuming there is one.
(3)
(0)Scroll down for more posts ▼
